<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971746</url>
  </required_header>
  <id_info>
    <org_study_id>GLPG4716-CL-101</org_study_id>
    <secondary_id>2021-001718-12</secondary_id>
    <nct_id>NCT04971746</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study With GLPG4716 and Nintedanib and Pirfenidone in Healthy Subjects</brief_title>
  <official_title>An Open-label, Fixed-sequence Drug-drug Interaction Study in Healthy Subjects to Evaluate the Effect of GLPG4716 on the Pharmacokinetics of Nintedanib and Pirfenidone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galapagos NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galapagos NV</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main aim of this study is to investigate the possible effect of GLPG4716 on the&#xD;
      pharmacokinetics (PK) of pirfenidone and nintedanib. Further aims are to investigate safety&#xD;
      and tolerability of GLPG4716 alone or administered simultaneously with pirfenidone or&#xD;
      nintedanib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of pirfenidone</measure>
    <time_frame>From Day 1 pre-dose until Day 15</time_frame>
    <description>To determine the effect of GLPG4716 on the PK of pirfenidone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) of pirfenidone</measure>
    <time_frame>From Day 1 pre-dose until Day 15</time_frame>
    <description>To determine the effect of GLPG4716 on the PK of pirfenidone</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of nintedanib</measure>
    <time_frame>From Day 1 pre-dose until Day 15</time_frame>
    <description>To determine the effect of GLPG4716 on the PK of nintedanib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-inf of nintedanib</measure>
    <time_frame>From Day 1 pre-dose until Day 15</time_frame>
    <description>To determine the effect of GLPG4716 on the PK of nintedanib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-emergent serious adverse events (SAEs), and TEAEs leading to treatment discontinuations.</measure>
    <time_frame>From Day 1 through study completion, an average of 2 months</time_frame>
    <description>To evaluate the safety and tolerability of GLPG4716 alone or when co-administered with pirfenidone or nintedanib.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>GLPG4716 and pirfenidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GLPG4716 and nintedanib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pirfenidone</intervention_name>
    <description>On Days 1 and 13, participants will receive an oral dose of pirfenidone.</description>
    <arm_group_label>GLPG4716 and pirfenidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GLPG4716</intervention_name>
    <description>From Day 3 to Day 14, participants will receive GLPG4716 daily.</description>
    <arm_group_label>GLPG4716 and nintedanib</arm_group_label>
    <arm_group_label>GLPG4716 and pirfenidone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nintedanib</intervention_name>
    <description>On Days 1 and 13, participants will receive an oral dose of nintedanib.</description>
    <arm_group_label>GLPG4716 and nintedanib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female between 18 and 55 years of age (extremes included), on the date of&#xD;
             signing the informed consent form (ICF). Female subjects should be of non-childbearing&#xD;
             potential.&#xD;
&#xD;
          -  A body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive.&#xD;
&#xD;
          -  Judged to be in good health by the investigator based upon the results of a medical&#xD;
             history, physical examination, vital signs, electrocardiogram (ECG), and fasting&#xD;
             clinical laboratory safety tests. Aspartate transaminase and alanine aminotransferase&#xD;
             must be no greater than the upper limit of normal (ULN). Other clinical laboratory&#xD;
             safety test results must be within the reference ranges or test results that are&#xD;
             outside the reference ranges need to be considered not clinically significant in the&#xD;
             opinion of the investigator&#xD;
&#xD;
        This list only includes the key inclusion criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to ingredients of GLPG4716, pirfenidone, or nintedanib or&#xD;
             history of a significant allergic reaction to ingredients of GLPG4716, pirfenidone, or&#xD;
             nintedanib as determined by the investigator.&#xD;
&#xD;
          -  Treatment with any medication (including over-the-counter (OTC) and/or prescription&#xD;
             medication, dietary supplements, nutraceuticals, vitamins and/or herbal supplements,&#xD;
             and hormonal replacement therapy) except occasional paracetamol (maximum dose of 2&#xD;
             g/day and maximum of 10 g/2 weeks) in the last 2 weeks or 5 half-lives of the drug,&#xD;
             whichever is longer, prior to the first dosing.&#xD;
&#xD;
        This list only includes the key exclusion criteria.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalia Rueda-Rincon, MD</last_name>
    <role>Study Director</role>
    <affiliation>Galapagos NV</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Galapagos Medical Information</last_name>
    <phone>+3215342900</phone>
    <email>medicalinfo@glpg.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nuvisan GmbH</name>
      <address>
        <city>Neu-Ulm</city>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

